ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -4.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | +8 | 116.88M | $20.55B | +11 | −4 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | — | 22.19M | $2.32B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 19.36M | — | $1.85B | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 2 | Capital World Investors ✦ | 16.65M | -11.9% | $1.59B | 0.2% | ▼ Trim | 5 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 15.15M | — | $1.45B | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 4 | State Street Global Advisors ✦ (passive) | 5.62M | -4.0% | $535.94M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 3.30M | +55.4% | $313.29M | 0.3% | ▲ Add | 5 | SEC ↗ ×8 |
| 6 | Geode Capital Management ✦ (passive) | 2.87M | +0.8% | $272.92M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 1.96M | -17.4% | $186.86M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 1.74M | -42.2% | $166.12M | 0.1% | ▼ Trim | 5 | SEC ↗ ×4 |
| 9 | ARK Investment Management ✦ | 1.17M | +30.5% | $111.45M | 0.8% | ▲ Add | 3 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 1.13M | — | $107.64M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 11 | Renaissance Technologies ✦ | 1.02M | -6.2% | $97.50M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 334.79K | +81.0% | $31.94M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Duquesne Family Office ✦ | 300.62K | New | $28.68M | 0.7% | New | 1 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 239.64K | +218.8% | $22.86M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 228.32K | -50.3% | $21.78M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 148.21K | +133.6% | $14.14M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 17 | Millennium Management ✦ | 121.53K | -63.4% | $11.59M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 120.86K | +3.9% | $11.53M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 19 | Marshall Wace ✦ | 59.65K | +49.0% | $5.69M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 20 | Wellington Management ✦ | 29.45K | -20.9% | $2.81M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 21 | Citadel Advisors ✦ | 26.89K | -91.2% | $2.57M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 17.83K | -76.3% | $1.70M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Duquesne Family Office | $28.68M | 0.7% |
Exited
| Icahn Capital | $17.45M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 837 holders, 154.80M shares, $18.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.50K sh · $1.63M
Director · 11.35K sh · $2.49M
Director · 100.65K sh · $21.98M
Director · 13.26K sh · $2.87M
Director · 9.96K sh · $2.21M
Director · 6.66K sh · $1.47M
Director · 13.72K sh · $3.01M
Director · 9.72K sh · $2.12M
Director · 14.20K sh · $3.08M
Director · 8.44K sh · $1.82M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology